T1	tradename 112 120	Oncaspar
T3	tradename 184 192	Oncaspar
T5	tradename 196 204	Oncaspar
T7	nanoparticle 206 219	pegaspargase)
T9	routeofadministration 235 248	intramuscular
T11	routeofadministration 252 263	intravenous
T13	fdaapprovaldate 291 295	1994
T15	tradename 381 389	Oncaspar
T17	chemoclass 396 422	asparagine specific enzyme
T19	indication 534 562	acute lymphoblastic leukemia
T21	indication 570 598	Acute lymphoblastic leukemia
T23	dose 669 670	2
T25	dose 671 697	500 International Units/m2
T27	routeofadministration 698 713	intramuscularly
T29	routeofadministration 717 730	intravenously
T31	routeofadministration 782 795	intramuscular
T33	routeofadministration 928 939	intravenous
T35	inactiveingredient 1004 1019	sodium chloride
T37	inactiveingredient 1023 1031	dextrose
T39	tradename 1116 1124	Oncaspar
T41	tradename 1396 1404	Oncaspar
T43	activeingredient 1451 1465	L-asparaginase
T45	activeingredient 1515 1529	L-asparaginase
T47	activeingredient 1593 1607	L-asparaginase
T49	adversereaction 1647 1658	Anaphylaxis
T51	adversereaction 1662 1688	serious allergic reactions
T53	tradename 1755 1763	Oncaspar
T55	adversereaction 1781 1808	serious allergic reactions.
T57	adversereaction 1816 1826	Thrombosis
T59	tradename 1841 1849	Oncaspar
T61	adversereaction 1867 1893	serious thrombotic events.
T63	adversereaction 1901 1913	Pancreatitis
T65	adversereaction 1958 1971	pancreatitis.
T67	tradename 1985 1993	Oncaspar
T69	adversereaction 2011 2024	pancreatitis.
T71	adversereaction 2032 2051	Glucose intolerance
T73	adversereaction 2138 2152	Hepatotoxicity
T75	adversereaction 2261 2279	allergic reactions
T77	adversereaction 2291 2303	anaphylaxis)
T79	adversereaction 2305 2344	central nervous system (CNS) thrombosis
T81	adversereaction 2346 2358	coagulopathy
T83	adversereaction 2360 2382	elevated transaminases
T85	adversereaction 2384 2402	hyperbilirubinemia
T87	adversereaction 2404 2417	hyperglycemia
T89	adversereaction 2423 2436	pancreatitis.
T91	company 2490 2515	Sigma-Tau Pharmaceuticals
T93	company 2517 2521	Inc.
T95	indication 2781 2815	Acute Lymphoblastic Leukemia (ALL)
T97	indication 2847 2875	Acute Lymphoblastic Leukemia
T99	adversereaction 3374 3385	Anaphylaxis
T101	adversereaction 3390 3416	Serious Allergic Reactions
T103	adversereaction 3460 3470	Thrombosis
T105	adversereaction 3511 3523	Pancreatitis
T107	adversereaction 3530 3556	Serious Allergic Reactions
T109	adversereaction 3562 3581	Glucose Intolerance
T111	adversereaction 3588 3598	Thrombosis
T113	adversereaction 3604 3616	Coagulopathy
T115	adversereaction 3623 3635	Pancreatitis
T117	adversereaction 3641 3655	Hepatotoxicity
T119	adversereaction 3660 3683	Abnormal Liver Function
T121	adversereaction 3690 3709	Glucose Intolerance
T123	adversereaction 3768 3786	Allergic Reactions
T125	indication 4092 4126	Acute Lymphoblastic Leukemia (ALL)
T127	tradename 4127 4135	Oncaspar
T129	indication 4252 4256	ALL.
T131	indication 4263 4291	Acute Lymphoblastic Leukemia
T133	tradename 4329 4337	Oncaspar
T135	indication 4443 4446	ALL
T137	activeingredient 4487 4502	L-asparaginase.
T139	tradename 4578 4586	Oncaspar
T141	dose 4590 4591	2
T143	dose 4592 4618	500 International Units/m2
T145	routeofadministration 4619 4634	intramuscularly
T147	routeofadministration 4638 4652	intravenously.
T149	tradename 4653 4661	Oncaspar
T151	frequency 4709 4723	every 14 days.
T153	tradename 4766 4774	Oncaspar
T155	routeofadministration 4791 4806	intramuscularly
T157	tradename 4970 4978	Oncaspar
T159	routeofadministration 5082 5095	intravenously
T161	tradename 5097 5105	Oncaspar
T163	routeofadministration 5287 5298	intravenous
T165	tradename 5675 5683	Oncaspar
T167	tradename 6232 6240	Oncaspar
T169	activeingredient 6285 6299	L-asparaginase
T171	activeingredient 6345 6359	L-asparaginase
T173	activeingredient 6419 6433	L-asparaginase
T175	adversereaction 6476 6487	Anaphylaxis
T177	adversereaction 6492 6530	Serious Allergic Reactions Anaphylaxis
T179	adversereaction 6535 6561	serious allergic reactions
T181	tradename 6594 6602	Oncaspar
T183	adversereaction 6617 6643	serious allergic reactions
T185	activeingredient 6712 6727	L-asparaginase.
T187	tradename 6781 6789	Oncaspar
T189	adversereaction 6868 6879	anaphylaxis
T191	routeofadministration 6915 6926	intravenous
T193	tradename 6967 6975	Oncaspar
T195	adversereaction 6993 7020	serious allergic reactions.
T197	adversereaction 7026 7062	Thrombosis Serious thrombotic events
T199	adversereaction 7074 7099	sagittal sinus thrombosis
T201	tradename 7132 7140	Oncaspar
T203	tradename 7156 7164	Oncaspar
T205	adversereaction 7182 7208	serious thrombotic events.
T207	adversereaction 7214 7239	Pancreatitis Pancreatitis
T209	tradename 7272 7280	Oncaspar
T211	tradename 7364 7372	Oncaspar
T213	adversereaction 7390 7403	pancreatitis.
T215	adversereaction 7409 7448	Glucose Intolerance Glucose intolerance
T217	tradename 7481 7490	Oncaspar.
T219	adversereaction 7506 7525	glucose intolerance
T221	adversereaction 7548 7587	Coagulopathy Increased prothrombin time
T223	adversereaction 7589 7626	increased partial thromboplastin time
T225	adversereaction 7633 7651	hypofibrinogenemia
T227	tradename 7684 7692	Oncaspar
T229	adversereaction 7897 7910	coagulopathy.
T231	adversereaction 7916 7930	Hepatotoxicity
T233	adversereaction 7935 7973	Abnormal Liver Function Hepatotoxicity
T235	adversereaction 7978 8001	abnormal liver function
T237	adversereaction 8332 8343	Anaphylaxis
T239	adversereaction 8348 8374	serious allergic reactions
T241	adversereaction 8413 8431	Serious thrombosis
T243	adversereaction 8470 8482	Pancreatitis
T245	adversereaction 8521 8540	Glucose intolerance
T247	adversereaction 8579 8591	Coagulopathy
T249	adversereaction 8630 8644	Hepatotoxicity
T251	adversereaction 8649 8672	abnormal liver function
T253	tradename 8750 8758	Oncaspar
T255	adversereaction 8763 8781	allergic reactions
T257	adversereaction 8793 8805	anaphylaxis)
T259	adversereaction 8807 8820	hyperglycemia
T261	adversereaction 8822 8834	pancreatitis
T263	adversereaction 8836 8875	central nervous system (CNS) thrombosis
T265	adversereaction 8877 8889	coagulopathy
T267	adversereaction 8891 8909	hyperbilirubinemia
T269	adversereaction 8911 8925	hepatotoxicity
T271	adversereaction 8930 8953	elevated transaminases.
T273	adversereaction 8955 8969	Hyperlipidemia
T275	adversereaction 8971 8991	hypercholesterolemia
T277	adversereaction 8996 9017	hypertriglyceridemia)
T279	tradename 9059 9068	Oncaspar.
T281	indication 9343 9346	ALL
T283	indication 9431 9434	ALL
T285	tradename 9448 9456	Oncaspar
T287	tradename 9784 9792	Oncaspar
T289	tradename 9845 9853	Oncaspar
T291	tradename 10048 10056	Oncaspar
T293	tradename 10341 10349	Oncaspar
T295	tradename 10402 10410	Oncaspar
T297	tradename 10966 10974	Oncaspar
T299	activeingredient 10983 10997	L-Asparaginase
T301	adversereaction 11013 11033	Abnormal Liver Tests
T303	adversereaction 11048 11071	Elevated Transaminases1
T305	adversereaction 11086 11104	Hyperbilirubinemia
T307	adversereaction 11120 11133	Hyperglycemia
T309	adversereaction 11148 11195	Central Nervous System Thrombosis Coagulopathy2
T311	adversereaction 11227 11239	Pancreatitis
T313	adversereaction 11366 11423	Prolonged prothrombin time or partial thromboplastin time
T315	adversereaction 11428 11447	hypofibrinogenemia.
T317	tradename 11753 11761	Oncaspar
T319	adversereaction 11768 11790	elevated transaminases
T321	adversereaction 11797 11809	coagulopathy
T323	adversereaction 11815 11828	hyperglycemia
T325	adversereaction 11834 11859	CNS thrombosis/hemorrhage
T327	adversereaction 11865 11877	pancreatitis
T329	adversereaction 11883 11909	clinical allergic reaction
T331	adversereaction 11919 11937	hyperbilirubinemia
T333	adversereaction 11970 11983	pancreatitis.
T335	indication 12004 12007	ALL
T337	indication 12126 12129	ALL
T339	tradename 12143 12151	Oncaspar
T341	tradename 12243 12251	Oncaspar
T343	indication 12297 12300	ALL
T345	tradename 12437 12445	Oncaspar
T347	adversereaction 12451 12478	clinical allergic reactions
T349	adversereaction 12480 12502	elevated transaminases
T351	adversereaction 12504 12522	hyperbilirubinemia
T353	adversereaction 12528 12543	coagulopathies.
T355	tradename 12590 12598	Oncaspar
T357	adversereaction 12614 12624	thrombosis
T359	adversereaction 12631 12644	hyperglycemia
T361	adversereaction 12681 12693	pancreatitis
T363	adversereaction 12705 12742	Allergic Reactions Allergic reactions
T365	adversereaction 12766 12778	bronchospasm
T367	adversereaction 12780 12791	hypotension
T369	adversereaction 12793 12808	laryngeal edema
T371	adversereaction 12810 12824	local erythema
T373	adversereaction 12828 12836	swelling
T375	adversereaction 12838 12851	systemic rash
T377	adversereaction 12857 12867	urticaria.
T379	indication 12880 12883	ALL
T381	tradename 12894 12910	Oncaspar-treated
T383	adversereaction 12941 12968	clinical allergic reactions
T385	adversereaction 13037 13054	allergic reaction
T387	indication 13193 13196	ALL
T389	indication 13230 13233	ALL
T391	activeingredient 13274 13286	asparaginase
T393	activeingredient 13383 13397	L-asparaginase
T395	activeingredient 13508 13523	L-asparaginase.
T397	adversereaction 13571 13598	clinical allergic reactions
T399	tradename 13602 13610	Oncaspar
T401	indication 13660 13663	ALL
T403	activeingredient 13708 13720	asparaginase
T405	adversereaction 13752 13779	clinical allergic reactions
T407	tradename 13783 13791	Oncaspar
T409	adversereaction 13829 13856	CLINICAL ALLERGIC REACTIONS
T411	tradename 14325 14341	Oncaspar-treated
T413	tradename 15193 15201	Oncaspar
T415	tradename 15339 15347	Oncaspar
T417	tradename 15512 15521	Oncaspar.
T419	tradename 15552 15560	Oncaspar
T421	tradename 15657 15665	Oncaspar
T423	tradename 15772 15780	Oncaspar
T425	tradename 15937 15945	Oncaspar
T427	tradename 16171 16183	Oncaspar did
T429	dose 16361 16363	10
T431	dose 16364 16390	000 International Units/m2
T433	tradename 16394 16402	Oncaspar
T435	routeofadministration 16409 16420	intravenous
T437	adversereaction 16464 16490	increase in liver enzymes.
T439	adversereaction 16520 16524	rash
T441	tradename 16748 16756	Oncaspar
T443	nanoparticle 16758 16771	pegaspargase)
T445	activeingredient 16775 16789	L-asparaginase
T447	corecomposition 16791 16819	L-asparagine amidohydrolase)
T449	surfacecoating 16853 16891	monomethoxypolyethylene glycol (mPEG).
T451	activeingredient 16892 16906	L-asparaginase
T453	chemoclass 16923 16929	enzyme
T455	molecularweight 16997 17005	34.5 kDa
T457	surfacecoating 17052 17056	mPEG
T459	activeingredient 17071 17085	L-asparaginase
T461	surfacecoating 17116 17120	mPEG
T463	molecularweight 17139 17145	5 kDa.
T465	tradename 17146 17163	Oncaspar activity
T467	activeingredient 17227 17241	L-asparaginase
T469	tradename 17353 17361	Oncaspar
T471	nanoparticle 17537 17549	pegaspargase
T473	inactiveingredient 17551 17575	dibasic sodium phosphate
T475	inactiveingredient 17592 17618	monobasic sodium phosphate
T477	inactiveingredient 17639 17654	sodium chloride
T479	inactiveingredient 17673 17678	water
T481	tradename 17778 17786	Oncaspar
T483	chemoclass 18115 18121	enzyme
T485	activeingredient 18122 18136	L-asparaginase
T487	routeofadministration 18418 18431	intramuscular
T489	tradename 18441 18449	Oncaspar
T491	dose 18451 18452	2
T493	dose 18453 18480	500 International Units/m2)
T495	activeingredient 18883 18895	asparaginase
T497	indication 19003 19006	ALL
T499	routeofadministration 19028 19041	intramuscular
T501	dose 19060 19061	2
T503	dose 19062 19088	500 International Units/m2
T505	tradename 19121 19129	Oncaspar
T507	eliminationhalflife 19148 19156	5.8 days
T509	tradename 19417 19425	Oncaspar
T511	indication 19585 19588	ALL
T513	tradename 19598 19606	Oncaspar
T515	dose 19610 19611	2
T517	dose 19612 19638	500 International Units/m2
T519	routeofadministration 19639 19654	intramuscularly
T521	frequency 19655 19669	every 2 weeks.
T523	tradename 19694 19702	Oncaspar
T525	plasmahalflife 19707 19720	3.2 1.8 days
T527	activeingredient 19788 19802	L-asparaginase
T529	plasmahalflife 19807 19820	5.7 3.2 days
T531	auc 19917 19952	9.5 4.0 International Units/mL/day
T533	auc 19999 20034	9.8 6.0 International Units/mL/day
T535	tradename 20232 20241	Oncaspar.
T537	tradename 20242 20244	No
T539	tradename 20315 20327	Oncaspar did
T541	indication 20527 20530	ALL
T543	tradename 20563 20575	Oncaspar was
T545	indication 20760 20763	ALL
T547	tradename 20787 20795	Oncaspar
T549	activeingredient 20814 20828	L-asparaginase
T551	tradename 20861 20869	Oncaspar
T553	routeofadministration 20887 20902	intramuscularly
T555	dose 20916 20917	2
T557	dose 20918 20944	500 International Units/m2
T559	activeingredient 21066 21080	L-asparaginase
T561	routeofadministration 21098 21113	intramuscularly
T563	dose 21127 21128	6
T565	dose 21129 21155	000 International Units/m2
T567	frequency 21156 21174	three times weekly
T569	tradename 21398 21406	Oncaspar
T571	activeingredient 21426 21440	L-asparaginase
T573	activeingredient 21829 21841	asparaginase
T575	tradename 21917 21925	Oncaspar
T577	activeingredient 21946 21960	L-asparaginase
T579	activeingredient 22276 22290	L-Asparaginase
T581	tradename 22291 22299	Oncaspar
T583	activeingredient 22379 22393	L-Asparaginase
T585	tradename 22506 22514	Oncaspar
T587	dose 22516 22517	2
T589	dose 22518 22544	500 International Units/m2
T591	routeofadministration 22545 22559	intramuscular)
T593	activeingredient 22632 22646	L-asparaginase
T595	dose 22648 22649	6
T597	dose 22650 22676	000 International Units/m2
T599	routeofadministration 22677 22691	intramuscular)
T601	frequency 22709 22723	3 times weekly
T603	tradename 22986 22994	Oncaspar
T605	activeingredient 23065 23079	L-asparaginase
T607	tradename 23147 23155	Oncaspar
T609	activeingredient 23175 23189	L-asparaginase
T611	indication 23312 23315	ALL
T613	activeingredient 23343 23355	Asparaginase
T615	tradename 23389 23397	Oncaspar
T617	indication 23493 23507	acute leukemia
T619	indication 23523 23527	ALL]
T621	activeingredient 23582 23595	asparaginase.
T623	activeingredient 23616 23628	asparaginase
T625	activeingredient 23877 23892	L-asparaginase.
T627	tradename 23915 23923	Oncaspar
T629	dose 23937 23938	2
T631	dose 23939 23947	000 or 2
T633	dose 23948 23974	500 International Units/m2
T635	routeofadministration 23988 24003	intramuscularly
T637	routeofadministration 24007 24020	intravenously
T639	frequency 24021 24035	every 14 days.
T641	tradename 24055 24063	Oncaspar
T643	indication 24354 24357	ALL
T645	activeingredient 24396 24421	L-asparaginase-containing
T647	tradename 24505 24513	Oncaspar
T649	indication 24642 24645	ALL
T651	activeingredient 24685 24700	L-asparaginase.
T653	tradename 24740 24748	Oncaspar
T655	nanoparticle 24750 24763	pegaspargase)
T657	activeingredient 24865 24879	L-asparaginase
T659	tradename 24925 24933	Oncaspar
T661	tradename 25043 25051	Oncaspar
T663	adversereaction 25132 25158	Serious Allergic Reactions
T665	adversereaction 25198 25224	serious allergic reactions
T667	adversereaction 25236 25247	anaphylaxis
T669	adversereaction 25333 25343	Thrombosis
T671	adversereaction 25487 25499	Pancreatitis
T673	adversereaction 25586 25605	Glucose Intolerance
T675	company 25769 25794	Sigma-Tau Pharmaceuticals
T677	company 25796 25800	Inc.
